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Abstract: Objective: To test the hypothesis that occlusion-positive (OP) patients with blepharospasm (BEB) or hemifacial 
spasm (HFS) will benefit from a Bangerter occlusion foil (BOF), compared to occlusion-negative (ON) patients. OP/ON 
was based on immediate improvement in spasm with placement of a hand in front of either eye. 
Design: Prospective non-randomised single-centre pilot study. 
Participants: Fifteen-patients (6 BEB, 9 HFS). 
Methods: Patients were identified as OP or ON and wore highest-density BOF tolerable over one spectacle lens for 1 
month. Outcomes were assessed at 1 month. 
Main Outcome Measures: Validated quality-of-life questionnaire (CDQ-24), scores of blink-rate and spasm severity 
assessed by two observers from video-recordings. 
Results: OP group had mean improvement in all scores. There was no change or worsening of scores in the ON group. In 
both BEB and HFS, more OP patients reported subjective benefit from wearing a foil (2 of 4 BEB, and 2 of 2 HFS) 
compared to the ON group (0 of 2 BEB, and 1 of 7 HFS). 
Conclusion: OP patients with BEB and HFS are more likely to experience improvement in spasms from wearing a BOF 
compared to ON patients. The occlusion test should be considered on all patients with BEB or HFS. 
Keywords: Essential blepharospasm, bangerter occlusion foils, occlusion test. 
INTRODUCTION 
  Benign essential blepharospasm (BEB) is characterised 
by bilateral involuntary spasmodic contraction of the eyelid 
protractors where aetiology is not known. Hemifacial spasm 
(HFS), in contrast is usually unilateral with an identifiable 
underlying cause, including a vascular loop or tumor 
compression of the facial nerve [1-3].
 
  Botulinum toxin (BT) and surgical extirpation of eyelid 
protractor muscles are the most effective treatments available 
[1-7]. Most patients with blepharospasm benefit from 
reduction of sensory triggers, particularly light, and tinted 
lenses can significantly reduce spasm in some patients [8-
11].
 Nearly 80% of patients with BEB report that bright light 
triggers or exacerbates their symptoms [3], and patients with 
BEB have been shown to be more light-sensitive than 
controls [8]. 
  Bangerter occlusion foils (BOF) are translucent, plastic 
filters that adhere to the front of a spectacle lens. They block 
light transmission and reduce visual acuity in a graded 
fashion. We previously reported a case of facial palsy-
induced bilateral blepharospasm, which improved with the 
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placement of a hand a few centimetres in front of either eye 
(“occlusion-positive”) [12]. The subsequent placement of a 
BOF over one spectacle lens has allowed this patient to 
remain asymptomatic without the need for any other 
treatments, including BT injections. 
  We have since observed a similar reduction in symptoms 
using the BOF in other occlusion-positive (OP) patients with 
BEB and curiously also with HFS. The aim of this pilot 
study was to test the hypothesis that the BOF improves 
symptoms of BEB and HFS in OP patients, but not 
occlusion-negative (ON) patients, helping establish the 
clinical utility of the occlusion-sign in identifying patients 
most likely to benefit from the BOF. 
METHODS 
Patients 
  This was a prospective non-randomised interventional 
pilot study approved by the Brighton West Research Ethics 
Committee and the Research and Development Committee 
of the Queen Victoria Hospital NHS Foundation Trust, East 
Grinstead, United Kingdom. Informed consent was obtained 
from all subjects prior to enrolment in the study. 
  Subjects with BEB or HFS were recruited from the 
Corneoplastic Unit Facial Dystonia Clinic. BEB was defined 
as involuntary spasmodic contractions of the eyelids not 2    The Open Ophthalmology Journal, 2010, Volume 4  Malhotra et al. 
associated with any known aetiology. HFS was defined as 
unilateral involuntary tonic-clonic contractions of the 
muscles innervated by the ipsilateral facial nerve. Of a total 
of 41 patients attending the Facial Dystonia clinic, 21 
eligible patients with BEB or HFS were identified. Sixteen 
patients agreed to initially participate, but one patient 
subsequently withdrew as she elected to have BT treatment 
one week into the study. Fifteen patients successfully 
completed the study, of which 9 had HFS and 6 had BEB. 
Five patients were unable to or refused to participate, 
including one patient with BEB who had tried the BOF 
previously without effect. Patients with secondary 
blepharospasm, predominantly monocular vision, or prone to 
falls were excluded from the study. 
Study Visits 
  Patients attended two study visits, at the beginning and 
end of a one-month period of wearing a Bangerter occlusion 
foil (BOF). To reduce the potential confounding effect of 
concurrent BT therapy, which the majority of participants 
were also receiving, the first study visit and commencement 
of BOF use was timed to occur just prior to the next 
scheduled BT injection, thus ensuring a maximal time 
interval from last injection. BT injections were therefore 
delayed on occasion by up to a month in a few patients. 
Patients were encouraged to continue using any other 
treatments for their dystonia, including tinted spectacles, 
during the study period. 
Data Collection 
  At the first (pre-intervention) study visit, all patients were 
assessed by the same ophthalmologist (ST). Baseline data 
included: age, gender, date of diagnosis of idiopathic facial 
dystonia, previous and current treatments, presence of other 
movement disorders, past ophthalmic and medical history, 
current medications, time from last BT treatment, current 
level of visual acuity and findings from a full ophthalmic 
examination to exclude secondary causes of blepharospasm. 
  Patients were identified as occlusion-positive (OP) or 
occlusion-negative (ON) depending on whether there was an 
immediate improvement in eyelid spasm with the placement 
of an examiner’s hand or occluder approximately 3cm in 
front of either eye, avoiding any direct facial or spectacle 
contact (Fig. 1a,  b).  Such an improvement was judged 
 
Fig. (1). (a, b) Occlusion test is performed with patient’s hand placed 3cm in front of the ipsilateral eye, avoiding facial or spectacle contact. 
(c) The Bangerter occlusion foil is a disposable self-adhesive foil, which can be cut to size to fit over a spectacle lens. 0.8 density foil shown 
here. (d) Bangerter occlusion foil (0.2 density) placed over right spectacle lens. Occlusion Status and Bangerter Occlusion Foils in Blepharospasm  The Open Ophthalmology Journal, 2010, Volume 4    3 
subjectively both by the examiner and also the patient and 
was defined as a reduction of at least 30% in frequency and 
severity of spasm. Patients from both the OP and ON groups 
were then fitted by an orthoptist with a single BOF (Haag 
Streit UK Ltd, Harlow Essex, UK) over one spectacle lens 
(Fig. 1c, d). The system of BOF and expected visual acuity 
for each density of foil is outlined in Table 1. The highest-
density BOF that was visually-tolerable for the patient was 
used, and patients were given a choice as to which eye they 
wished to wear the BOF over. Patients who did not regularly 
wear spectacles were provided with clear frames, whilst 
those who had separate reading and distance spectacles were 
given a separate BOF for each pair of glasses. Patients were 
asked to wear the BOF for a one-month period, at the end of 
which they attended their second (post-intervention) study 
visit. 
Table  1.  Bangerter Occlusion Foils –Grading of Foil and 
Expected Visual Acuity 
 









LP Light  Perception 
00 No  light 
 
Outcome Measures 
  The effect of wearing the BOF on facial dystonia over 
the one-month intervention period was measured with a 
quality-of-life questionnaire (QOL) and video-recordings of 
patients, conducted at both the first and second study visits. 
  The CDQ-24 questionnaire, a validated disease-specific 
QOL designed to assess the level of impairment resulting 
from a patient’s craniocervical dystonia, has been shown to 
be both reliable and sensitive in measuring treatment-
induced changes over a 4-week and 1-year period [13]. The 
24-item questionnaire is based on five sub-scales that 
address stigma, emotional well-being, pain, activities of 
daily living and social/family life, with each item consisting 
of five statements representing increasing severity of 
impairment, scored from 0 to 4. Patients completed the same 
questionnaire at the first and second study visits, and at the 
latter, were asked to record their level of impairment during 
the one-month intervention period. Change in total score as 
well as scores for each of the five subscales between the first 
and second study visit questionnaires were assessed for each 
patient. 
  Video-recordings of patients over an uninterrupted 2-
minute interval were also taken at pre and post-intervention 
study visits. At the second study visit, patients were recorded 
with the BOF being worn. The tapes were viewed at a later 
date by two independent observers, one masked and one 
unmasked to the occlusion-status of the patients, and the 
blink-rate and frequency and severity of involuntary 
movements were scored in a method similar to that described 
by Vitale et al. [14]. The number of blinks was counted over 
the 2-minute interval. The frequency of involuntary 
movements was scored from 0-3 in the following order: no 
involuntary movement (0), movement present <10% of time 
(1), movement present >10% of time (2) and movement 
present constantly (3). The severity of involuntary movement 
was scored from 0-3 in the following order: no involuntary 
movement (0), increased blinking and/or mild involuntary 
facial movement (1), forced closure of eyelids and/or 
moderate involuntary facial movement (2) and severe forced 
closure of eyelids and/or severe involuntary facial movement 
(3). 
  Blink-rate and scores used for analysis was taken as the 
average of the two video observers’ scores. Changes in 
blink-rate and scores between the first and second study visit 
were assessed. 
Statistical Analysis 
  Differences between pre- and post-intervention scores for 
CDQ-24 questionnaires and video-ratings were calculated 
for each patient. Since the differences were not normally 
distributed, the non-parametric Mann-Whitney test was used 
to compare the occlusion-positive and occlusion-negative 
groups. A two-tailed 5% significance level was used 
throughout. The analysis was carried out using SPSS version 
14 software (SPSS Inc. Chicago). 
RESULTS 
  Fifteen-patients (6 with BEB, 9 with HFS) completed the 
study. Six (40%) patients (5 female, 1 male) were occlusion-
positive (OP) and 9 (5 female, 4 male) were occlusion-
negative (ON). Of the 9 patients with HFS, 2 were OP and 7 
were ON. Of the 6 with BEB, 4 were OP and 2 were ON. 
Mean age was 63.3 years (range 44-80 years) and 73.5 years 
(range 43-93 years) for the OP and ON groups, respectively. 
Previous/Concurrent Treatments 
  14 of the 15 patients were receiving regular BT injections 
at time of enrolment. 1 patient in the OP group, who had 
already been successfully using the BOF prior to enrolment 
in the study, had not required BT injections for three years. 
All patients (100%, 14/14) commenced the study at least 4 
weeks after their last BT injection, with the median time 
from last injection being 12 weeks (range 4 weeks-36 weeks) 
in the OP group and 15 weeks (range 4-42 weeks) in the ON 
group. 
  All patients had tried tinted spectacles with varying 
success. One patient found pinhole spectacles beneficial in 
relieving blepharospasm. Three patients (1 OP and 2 ON) 
had undergone previous limited orbiculectomy surgery. 
BOF Use 
  The majority of patients in both groups (80% OP, 67% 
ON) wore the BOF full-time (all waking hours). The 
remaining patients elected not to wear the BOF whilst at 
work, or only at certain times of the day, and in these 4    The Open Ophthalmology Journal, 2010, Volume 4  Malhotra et al. 
patients the time of use ranged from 4-8 hours per day. The 
mean strength of BOF worn was 0.45 (range 0.3-0.6) in the 
OP group and 0.58 (range 0.4-0.8) in the ON group. 
Outcomes 
  There was a difference in the mean change from pre to 
post-intervention scores between OP and ON groups (Table 
2). There was a positive mean change (improvement) 
between pre and post-intervention scores for total CDQ-24 
score, frequency and severity of involuntary movement 
score, and blink-rate in the occlusion-positive group. In 
contrast, there was no change or a negative mean change 
(worsening) of these scores and blink-rate in the occlusion-
negative group. This difference in mean change between the 
OP and ON groups was statistically significant for blink-rate 
(p=0.029) and severity of spasm (p=0.019). 
  Of the 9 patients with HFS, those who were OP (2) 
reported a subjective benefit from the Bangerter foil. Of 
those who were ON (7), 1 reported a subjective benefit, 
whilst the remaining 6 did not report any benefit from 
wearing the foil. 
  Of the 6 patients with BEB, 4 who were OP reported a 
subjective benefit from wearing the foil, whilst 2 did not 
report any subjective benefit. None of the patients who were 
ON (2) reported any subjective benefit (Table 3). 
Complications of BOF Use 
  There were no significant reported complications from 
patients in either group from wearing the BOF. 
DISCUSSION 
  The results of this pilot study support our hypothesis that 
occlusion-positive patients with BEB or HFS are more likely 
to experience a reduction in their symptoms from wearing 
the BOF, than those who are occlusion-negative. When 
measured subjectively with the CDQ-24 QOL, and 
objectively with observation of blink-rate, frequency and 
severity of spasm, OP patients showed a statistically 
significant difference in improvement for blink-rate and 
severity of blepharospasm compared to ON patients. 
 Anderson  et al. [3] have suggested a simple conceptual 
approach to the multiple factors underlying the origin and 
manifestations of BEB. They propose that blepharospasm is 
due to a defective neurological circuit rather than a specific 
defective locus. Afferent stimuli, such as light and ocular 
irritation, are transmitted via the optic and trigeminal nerves 
to an as-yet-unidentified control centre, which may be 
located in the basal ganglia, midbrain or brainstem. 
Dysfunction of this centre results in failure of modulation of 
efferent signals transmitted by the facial nerve to the eyelid 
protractors, leading to involuntary eyelid contracture. This 
aberrant cycle becomes self-perpetuating as the resultant 
eyelid spasms create further irritation of the eyes, which will 
act as sensory stimuli [3]. Sensory triggers for BEB include 
bright light and ocular irritation [3, 8, 16]. Both FL41-tinted 
and grey-tinted lenses can significantly improve 
blepharospasm [9, 11]. 
  Perhaps more curious is the finding of occlusion-
positivity and the effect of the BOF in patients with HFS. 
HFS has traditionally been considered to be due to an 
identifiable underlying condition affecting the facial nerve. 
Furthermore, just as in facial palsy-induced blepharospasm, 
where in an isolated case we first found the BOF to be 
effective, patients with HFS also tend not to be light-
sensitive or photophobic [12].
 Interestingly, prior facial-palsy 
has been recognised in up to 1 in 4 cases of HFS and perhaps 
electrophysiology may play a more valuable role in 
identifying such patients and possibly helping further 
understand the basis of occlusion-positivity [15, 16]. 
However, we have also anecdotally observed that some 
patients with HFS experience reduction in their lower facial 
as well as eyelid spasm from wearing FL-41 tinted spectacle 
lenses. We believe that the role and thus modulation of 
sensory stimuli in HFS therefore remains an area that 
requires further study. 
  The BOF degrades visual acuity by reducing light 
transmission, and may improve blepharospasm by reducing 
noxious light or other complex visual stimuli mediated by 
the trigeminal and optic nerves into the aberrant blink cycle. 
All patients in the study had used tinted lenses with variable 
success. As no measurements of light-sensitivity were made, 
Table 2.  Mean Change (Pre-Intervention Minus Post-Intervention) in Outcome Scores 
 
Mean Change
  Occlusion-Positive Occlusion-Negative  Exact Significance of Difference Between OP and ON Groups  
(Mann-Whitney Test) 
CDQ24 Total Score  7.2 -2.7  0.147 
 a. Stigma   3.6  -0.6  0.147 
 b. Emotional  1.2  0.2  0.518 
 c. Pain  1.4  0.0  0.147 
 d. ADL  1.0  -2.7  0.438 
 e. Social  0.0  0.3  0.699 
Blink-Rate 39.8  -20.4  0.029 
Frequency of Movement  1.2  0.3  0.240 
Severity of Movement  1.4  -0.1  0.019 
a-e = the five subscales of the 24-item CDQ-24 QOL. 
NB. A positive mean indicates that the post-treatment value is lower than the pre-treatment value (improvement), whilst a negative mean indicates that the post-treatment value is 
higher than the pre-treatment value (worsening). Occlusion Status and Bangerter Occlusion Foils in Blepharospasm  The Open Ophthalmology Journal, 2010, Volume 4    5 
it is not possible to comment on whether the OP patients 
were more light-sensitive or had more light-induced spasm 
than ON patients, but this may have influenced response 
rates between the two groups. 
  Many questions remain unanswered about the 
mechanism of action of the BOF on reducing spasm, and 
these should be the subject of further study. Firstly, if 
reduction in light transmission is their main effect, why do 
they work with unilateral wear, and would we have expected 
a greater effect if they had been worn bilaterally, as tinted 
lenses are? Inducing visual blur bilaterally would be 
impractical and unacceptable to most patients. It has also 
been our experience that unilateral wear evokes a sufficient 
response in those patients responsive to the BOF, and that 
this response is the same regardless of the side of wear (left 
or right), even in our HFS patients. These observations 
suggest that the underlying mechanism for the BOF is much 
more complex than just reduction in light transmission or 
vision. It may well simply act as a distraction, but 
nevertheless, this possible distraction-effect remained for the 
duration of the study and further studies may help define 
long-term benefit. 
  We acknowledge significant flaws in this study. 
Confounding factors that may have influenced outcomes in 
the two groups include placebo effect, selection bias, and 
duration of wear and strength of BOF. As patients were 
aware of the working hypothesis on enrolment into the study, 
and were not masked to their occlusion status, a placebo 
effect in the OP group may have contributed to their better 
overall results. 
  The better results obtained in the OP groups may also 
have been due to selection bias, as 50% of the OP group 
(3/6) had already been using the BOF for blepharospasm 
with good effect prior to enrolment. 
  It would be expected that patients who wore the BOF 
more consistently, and who tolerated more reduction in 
visual acuity, would gain more effect. Whilst a greater 
proportion of the OP group (80%) wore the BOF full-time 
compared to the ON group (67%), and the mean strength of 
foil used was also stronger in the OP group (0.45) than in the 
ON group (0.58), the small numbers of patients in both 
groups did not allow meaningful statistical analysis of this 
difference. However, duration of wear and strength of BOF 
prescribed is patient-driven and reflects what is acceptable to 
patients in everyday life. Enforcing a certain strength and 
duration of wear between the OP and ON patients in this 
study may have increased the accuracy of our results, but 
would not have reflected how we would practically prescribe 
this treatment to our patients. The strength of BOF worn 
ranged between 0.3-0.6 in the OP group, equating to a 
unilateral reduction of vision of 20/30-20/80 (mean 20/40). 
This did not affect patients’ ability to carry out normal daily 
tasks; however, patients often opted not to use the BOF 
during activities such as work, where clear binocular vision 
was essential. In our study we excluded patients who were 
predominantly monocular, however, unilateral blur may 
contribute to loss of depth perception and impair mobility in 
patients who are already impaired, many of whom may also 
be elderly. This further limits the suitability of BOF or other 
uniocular occlusion modalities. 
Table 3.  Individual Changes (Pre-Intervention Minus Post-Intervention) in Outcome Scores 
 
Patient  CDQ24  
Total Score 







1 HFS  3  0  1  0  2  0  -32  2  1 
2 HFS  2  4  0  0  -3  1  17  1  1 
3 BEB  36  9  4  7  11  5  125  3  3 
4 BEB  -14  -1  -5  0  -4  -4  12  0  0 
5 BEB  11  4  4  0  4  2  38  1  1 
6 BEB  9  6  6  0  -1  -2  77  0  2 
Occlusion-Negative Patients 
7 BEB  -4  -2  1  8  -11  0  -49  0  -1 
8 BEB  2  2  -1  -1  2  0  -15  0  0 
9 HFS  -10  0  -3  -1  -6  0  -20  0  -1 
10 HFS  -4  -3  -1  0  -2  2  1  0  0 
11 HFS  -5  -3  1  0  -2  -1  -38  1  1 
12 HFS  0  0  3  -3  0  0  -55  1  0 
13 HFS  14  8  6  -1  0  1  6  0  0 
14 HFS  -17  -8  -2  -2  -5  0  -2  1  0 
15 HFS  0  1  0  0  0  1  -12  0  0 
a-e = the five subscales of the 24-item CDQ-24 QOL. 6    The Open Ophthalmology Journal, 2010, Volume 4  Malhotra et al. 
  With no conceivable cure in sight and current treatments 
offering variable symptomatic control, any treatment which 
is safe, effective, affordable and acceptable to patients, is a 
welcome addition to the evidence-based management of this 
difficult condition. The BOF meets many of these criteria. 
There were no significant side effects from wearing the BOF 
in this study, but practical problems, such as the 
accumulation of dirt and bubbles under the stick-on foil, 
which increased visual blur, occurred. This was easily 
rectified by changing of this cheap foil (approximately 4 US 
dollars each). Whilst one OP patient in this study has not 
required any BT since wearing the BOF, all other patients 
have required ongoing BT injections for optimal 
blepharospasm control. We anticipate that the impact of the 
BOF will be as an adjunctive to the mainstay treatments of 
BT and surgery. It remains to be seen whether the BOF can 
reduce the amount or frequency of BT required in responsive 
patients, but this would clearly be beneficial. 
  In conclusion, the results of this small pilot study suggest 
that patients with idiopathic blepharospasm or HFS may 
demonstrate the phenomenon of occlusion-positivity. Those 
positive are more likely to experience a reduction in spasm 
with a BOF than occlusion-negative patients. Whilst further 
study with larger patient numbers is required, we suggest 
that patients with BEB or HFS be examined for occlusion 
status, and that the BOF be considered as an adjunctive 
treatment in patients who are occlusion-positive. 
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